Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency

Journal of Urology

Volumn 189, Issue 1 SUPPL, 2013, Pages

  Kaplan, Steven A ^a   McCammon, Kurt ^b   Fincher, Roger ^c   Fakhoury, Allam ^d   He, Weizhong ^d  

^a Department of Obstetrics Gynecology   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Deaconess Medical Building ^*  (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

adrenergic alpha antagonists; muscarinic antagonists; overactive; urinary bladder

Indexed keywords

PLACEBO; SOLIFENACIN; TAMSULOSIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CATHETERIZATION; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MICTURITION; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATIENT PERCEPTION OF BLADDER CONDITION SCORE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URGENCY PERCEPTION SCALE; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; XEROSTOMIA;

EID: 84870948101     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.030     Document Type: Article

References (22)

1. P. Abrams, L. Cardozo, M. Fall The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Urology 61 2003 37
2. C.R. Chapple, C.G. Roehrborn A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder Eur Urol 49 2006 651
3. G.E. Lemack Defining the role of overactive bladder treatments in men with lower urinary tract symptoms Nat Clin Pract Urol 4 2007 174
4. R. Dmochowski Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep 7 2006 462
5. T. Knutson, C. Edlund, M. Fall BPH with coexisting overactive bladder dysfunction-an everyday urological dilemma Neurourol Urodyn 20 2001 237
6. T.J. Peters, J.L. Donovan, H.E. Kay The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms J Urol 157 1997 885
7. C.G. Roehrborn, P. Abrams, E.S. Rovner Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence BJU Int 97 2006 1003
8. S.A. Kaplan, K. Walmsley, A.E. Te Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia J Urol 174 2005 2273
9. P. Abrams, S. Kaplan, H.J. De Koning Gans Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction J Urol 175 2006 999
10. S.A. Kaplan, A.J. Wein, D.R. Staskin Urinary retention and post-void residual urine in men: separating truth from tradition J Urol 180 2008 47
11. B.T. Blake-James, A. Rashidian, Y. Ikeda The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis BJU Int 99 2007 85
12. G. Novara, A. Galfano, V. Ficarra Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review Eur Urol 50 2006 675
13. K.S. Coyne, L.S. Matza, Z. Kopp The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder Eur Urol 49 2006 1079
14. L. Cardozo, K.S. Coyne, E. Versi Validation of the urgency perception scale BJU Int 95 2005 591
15. M.J. Barry, F.J. Fowler Jr, M.P. O'Leary The American Urological Association symptom index for benign prostatic hyperplasia The Measurement Committee of the American Urological Association J Urol 148 1992 1549
16. C.R. Chapple, L. Cardozo, W.D. Steers Solifenacin significantly improves all symptoms of overactive bladder syndrome Int J Clin Pract 60 2006 959
17. Boehringer Ingelheim Flomax® (tamsulosin hydrochloride) Full Prescribing Information March, 2008
18. S.A. Kaplan, C.G. Roehrborn, E.S. Rovner Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319
19. S. De Wachter, J.J. Wyndaele Voiding chart data to study lower urinary tract function non-invasively: critical review of the parameter "voiding frequency" Poster presented at the 21st Annual European Association of Urology (EAU) Congress Abstract 533 http://www.uroweb.org/publications/eau- abstracts-online/?id=312&no-cache=1&AID=8356 Accessed February 5, 2009
20. A. Seim, C. Hoyo, T. Ostbye The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study BJU Int 96 2005 88
21. C. Chapple, S. Herschorn, P. Abrams et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers Eur Urol 56 2009 534
22. S. MacDiarmid, A. Rogers Male overactive bladder: the role of urodynamics and anticholinergics Curr Urol Rep 8 2007 66